Home  |  Contact

UniProtKB/Swiss-Prot P38398: Variant p.Ser1187Ile

Breast cancer type 1 susceptibility protein
Gene: BRCA1
Variant information

Variant position:  1187
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Serine (S) to Isoleucine (I) at position 1187 (S1187I, p.Ser1187Ile).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from small size and polar (S) to medium size and hydrophobic (I)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In BC and BROVCA1.
Any additional useful information about the variant.



Sequence information

Variant position:  1187
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1863
The length of the canonical sequence.

Location on the sequence:   ENDIKESSAVFSKSVQKGEL  S RSPSPFTHTHLAQGYRRGAK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ENDIKESSAVFSKSVQKGELSRSPSPFTHTHLAQGYRRGAK

Gorilla                       KNDIKESSAVFSKNVQRGELSRSPSPFTHTHLAQGYRRGAK

                              ESDIKEKSAVFSKSVQSGEFSRSPSPSDHTRLAQGYQRGTK

Rhesus macaque                ANDIKESSAVFSKSIQRGELSRSPSPFTHTHLAQGYQKEAK

Chimpanzee                    ENDIKESSAVFSKSVQRGELSRSPSPFTHTHLAQGYRRGAK

Mouse                         EGDIMERSAVFNGSILRRESSRSPSPVTHASKSQSLHRASR

Rat                           EGGITEKSAIFNGSVLRRESSRSPSPVTHASKSRSLHRGSR

Bovine                        ESDIKERSAVFSESVQKGEFRGSPGPFTHTHLAQGHQRGAG

Caenorhabditis elegans        SSQDLENIKIMTAS---ESLETPPEPI--------------

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 1863 Breast cancer type 1 susceptibility protein
Region 1181 – 1216 Disordered
Compositional bias 1181 – 1196 Polar residues
Modified residue 1189 – 1189 Phosphoserine
Modified residue 1191 – 1191 Phosphoserine
Alternative sequence 64 – 1863 Missing. In isoform 2.
Alternative sequence 224 – 1365 Missing. In isoform 5.
Alternative sequence 264 – 1366 Missing. In isoform 3 and isoform 6.


Literature citations

Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
Valarmathi M.T.; Sawhney M.; Deo S.S.V.; Shukla N.K.; Das S.N.;
Hum. Mutat. 23:205-205(2004)
Cited for: VARIANTS BC/BROVCA1 LYS-10; LYS-23; ILE-1187; HIS-1200 AND TYR-1217; VARIANTS BC ILE-1204 AND ASN-1207; VARIANTS BROVCA1 LEU-1226 AND GLY-1243; VARIANT ARG-1183;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.